Previous 10 | Next 10 |
2023-08-04 09:45:22 ET Alector, Inc. (ALEC) Q2 2023 Results Conference Call August 03, 2023 04:30 PM ET Company Participants Katie Hogan - Senior Director of Corporate Communication and Investor Relations Dr. Arnon Rosenthal - Co-Founder and CEO Dr. Sara Kenkare-...
2023-08-03 16:29:39 ET Alector press release ( NASDAQ: ALEC ): Q2 EPS of $0.02 may not be comparable to consensus of -$0.82. Revenue of $56.21M (-29.6% Y/Y) beats by $52.03M . For further details see: AlectorEPS of $0.02, revenue of $56.21M beats by $52.03M
Closed screening in the INVOKE-2 Phase 2 trial of AL002 in participants with early Alzheimer’s disease; completing enrollment in Q3 2023, with data readout expected in Q4 2024 Presented update on INVOKE-2 at the Alzheimer’s Association International Conference (AAIC) ...
SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Thursday, August 3, 2023, at 4:30 p.m. ET to discuss results for the secon...
2023-07-17 03:39:55 ET Summary Alector, a clinical-stage biopharmaceutical company, pioneers immuno-neurology treatments with three product candidates targeting different pathologies. Q1 2023 financial results reveal a net loss of $45.9M and a decrease in collaboration revenue to ...
2023-07-13 17:25:28 ET Gainers: ACADIA Pharmaceuticals ( ACAD ) +29% . Intuitive Machines ( LUNR ) +25% . Atara Biotherapeutics ( ATRA ) +5% . Xilio Therapeutics ( XLO ) +5% . Alector ( ALEC ) +3% . Losers: Theseus ...
2023-06-11 12:00:02 ET Driven by novel therapeutics from Biogen ( NASDAQ: BIIB )/ Eisai ( OTCPK:ESALF ) and Eli Lilly ( NYSE: LLY ), the Alzheimer’s disease market across eight major countries will reach $13.7B in 2030, the data analytics firm, GlobalData said las...
SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Goldman Sachs 44 th Annual Global Healthcare Confere...
2023-05-14 12:00:49 ET Leqembi, the new Alzheimer's therapy developed by Biogen ( NASDAQ: BIIB ) and Eisai ( OTCPK:ESALF ) ( OTCPK:ESAIY ), could add $2B - $5B costs to Medicare annually, in the event of broader coverage, according to a recently published study. Early th...
2023-05-04 17:21:11 ET Alector press release ( NASDAQ: ALEC ): Q1 GAAP EPS of -$0.55. Revenue of $16.5M. For further details see: Alector GAAP EPS of -$0.55, revenue of $16.5M
News, Short Squeeze, Breakout and More Instantly...
--INVOKE-2 is the first global Phas e 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative stud...
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Associatio...
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5 th Annual Neuro Pers...